Drugs for Lung Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 70)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Carboplatin |
Approved |
Phase 4 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
2 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 4 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
3 |
|
Everolimus |
Approved |
Phase 4 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
4 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
5 |
|
Antimitotic Agents |
|
Phase 4 |
|
|
|
6 |
|
Tubulin Modulators |
|
Phase 4 |
|
|
|
7 |
|
Albumin-Bound Paclitaxel |
|
Phase 4 |
|
|
|
8 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
9 |
|
Bevacizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
10 |
|
Vinorelbine |
Approved, Investigational |
Phase 3 |
|
71486-22-1 |
44424639 60780 |
Synonyms:
5' Nor anhydrovinblastine
5'-Noranhydrovinblastine
5'-Nor-anhydrovinblastine
Navelbine
Navelbine Base
Vinorelbin
Vinorelbina
Vinorelbina [Spanish]
|
Vinorelbine
VINORELBINE BASE
Vinorelbine bitartrate
Vinorelbine ditartarate
Vinorelbine ditartrate
Vinorelbine tartrate
Vinorelbinum
Vinorelbinum [Latin]
|
|
11 |
|
Gefitinib |
Approved, Investigational |
Phase 3 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
12 |
|
Cetuximab |
Approved |
Phase 3 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
13 |
|
Antineoplastic Agents, Immunological |
|
Phase 2, Phase 3 |
|
|
|
14 |
|
Immunoglobulins, Intravenous |
|
Phase 2, Phase 3 |
|
|
|
15 |
|
Immunoglobulins |
|
Phase 2, Phase 3 |
|
|
|
16 |
|
Antibodies, Monoclonal |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Antibodies |
|
Phase 2, Phase 3 |
|
|
|
18 |
|
Angiogenesis Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
19 |
|
Mitogens |
|
Phase 3 |
|
|
|
20 |
|
Shark Cartilage |
|
Phase 3 |
|
|
|
21 |
|
Immunoglobulin G |
|
Phase 3 |
|
|
|
22 |
|
Endothelial Growth Factors |
|
Phase 3 |
|
|
|
23 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
24 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
25 |
|
Erlotinib |
Approved, Investigational |
Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
26 |
|
Bortezomib |
Approved, Investigational |
Phase 2 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
27 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
28 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
29 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
30 |
|
Picropodophyllin |
Approved, Investigational |
Phase 2 |
|
518-28-5, 477-47-4 |
10607 72435 |
Synonyms:
(−)-podophyllotoxin
(-)-Podophyllotoxin
6,7]NAPHTHO[2,3-D][1,3]DIOXOL-6(5AH)-ONE
9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDROFURO[3',4'
9-HYDROXY-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-D][1,3]dioxol-6(5ah)-one
Ardern brand OF podophyllotoxin
AXL-1717
AXL1717|podofilox
Canderm brand OF podophyllotoxin
Condyline
Condylox
CPH86
Epipodophyllotoxin
Fides ecopharma brand OF podophyllotoxin
Hamilton brand OF podophyllotoxin
Newport brand OF podophyllotoxin
NSC-24818
NSC-36407
Oclassen brand OF podophyllotoxin
Paddock brand OF podophyllotoxin
Paladin brand OF podophyllotoxin
|
PICROPODOPHYLLIN
PICROPODOPHYLLOTOXIN
PODOCON-25
Podofilm
Podofilox
Podophyllinate lactone
Podophyllinic acid lactone
Podophyllotoxin
Podophyllotoxin 7
PODOPHYLLOTOXIN PICROPODOPHYLLIN
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-isomer
PPT
Stiefel brand OF podophyllotoxin
Wartec
Warticon
Wolff brand OF podophyllotoxin
Yamanouchi brand OF podophyllotoxin
|
|
31 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
32 |
|
Rucaparib |
Approved, Investigational |
Phase 2 |
|
283173-50-2 |
9931954 |
Synonyms:
AG014699
AG-014699
AG-014699|AG014699|AG14447|PF-01367338|Rubraca®
AG14447
AG-14447
|
AG-14447ag-014699Rucaparib
PF-01367338
Rubraca
RUCAPARIB
Rucaparibum
|
|
33 |
|
Metformin |
Approved |
Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
34 |
|
Pembrolizumab |
Approved |
Phase 1, Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
35 |
|
Fludarabine |
Approved |
Phase 1, Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Β-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Β-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
36 |
|
Aldesleukin |
Approved |
Phase 1, Phase 2 |
|
110942-02-4 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukin
Aldesleukina
IL-2
ILT101
ILT-101
Interleukin-2 aldesleukin
|
INTERLEUKIN-2 PRECURSOR
Interleukin-2(2-133),125-ser
Recombinant human interleukin-2
Recombinant interleukin-2 human
T-CELL GROWTH FACTOR
TCGF
|
|
37 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 1, Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
38 |
|
Coenzyme M |
Approved, Investigational |
Phase 1, Phase 2 |
|
3375-50-6 |
598 23662354 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-Mercaptoethanesulphonic acid
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzym m
Coenzyme m
CoM
D-7093
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
NSC-113891
Reduced coenzyme m
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Β-mercaptoethanesulfonate
Β-mercaptoethanesulfonic acid
Β-mercaptoethanesulphonate
Β-mercaptoethanesulphonic acid
|
|
39 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 2 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
40 |
|
Pemetrexed |
Approved, Investigational |
Phase 2 |
|
150399-23-8, 137281-23-3 |
60843 446556 135565230 |
Synonyms:
(2R)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate
ALIMTA
Alimta®|LY-231514
Disodium, pemetrexed
LY-2315
LY231514
|
LY-231514
MTA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-D)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NSC-698037
Pemetrexed
Pemetrexed disodium
|
|
41 |
|
Crizotinib |
Approved, Investigational |
Phase 2 |
|
877399-52-5 |
11626560 |
Synonyms:
(<i>R</i>)-crizotinib|PF 2341066|PF-02341066|PF-2341066|PF2341066|Xalkori®
(R)-CRIZOTINIB
CRIZOTINIB
Crizotinibum
PF 2341066
|
PF-02341066
PF2341066
PF-2341066
XALKORI
|
|
42 |
|
Glutamic acid |
Approved, Nutraceutical |
Phase 2 |
|
56-86-0 |
33032 |
Synonyms:
(+)-Estrone
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-beta-D-Glucopyranosyl-beta-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(2R)-2,3-Dihydroxypropanoic acid
(2S)-2-Aminopentanedioate
(2S)-2-Aminopentanedioic acid
(3R,4S,5R)-5-[(1R)-1-Carboxy-2,2-difluoro-1-(phosphonooxy)ethoxy]-4-hydroxy-3-(phosphonooxy)cyclohex-1-ene-1-carboxylate
(R)-2,3-Dihydroxypropanoic acid
(R)-Glycerate
(R)-Glyceric acid
(S)-(+)-Glutamate
(S)-(+)-Glutamic acid
(S)-2-Aminopentanedioate
(S)-2-Aminopentanedioic acid
(S)-Glutamate
(S)-Glutamic acid
1,3,5(10)-Estratrien-3-ol-17-one
1-Amino-2-hydroxyethane
1-Aminopropane-1,3-dicarboxylate
1-Amino-propane-1,3-dicarboxylate
1-Aminopropane-1,3-dicarboxylic acid
1-Amino-propane-1,3-dicarboxylic acid
2 Acetamido 2 deoxy D glucose
2 Acetamido 2 deoxyglucose
2 Aminoethanol
2-Acetamido-2-deoxy-D-glucose
2-Acetamido-2-deoxyglucose
2-Amino-1-ethanol
2-Aminoethan-1-ol
2-Aminoethanol
2-Amino-ethanol
2-Aminoethyl alcohol
2-Aminoglutarate
2-Aminoglutaric acid
2-Aminopentanedioate
2-Aminopentanedioic acid
2-Ethanolamine
2-Hydroxyethanamine
2-Hydroxyethylamine
3a,7a,12a-Trihydroxy-5b-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid-24-glycine
3alpha,7alpha,12alpha-Trihydroxy-N-(carboxymethyl)-5beta-cholan-24-amide
3-Hydroxy-1,3,5(10)-estratrien-17-one
3-Hydroxy-17-keto-estra-1,3,5-triene
3-Hydroxyestra-1,3,5(10)-trien-17-one
3-Hydroxyestra-1,3,5(10)-triene-17-one
3-Hydroxyoestra-1,3,5(10)-trien-17-one
3Α,7α,12α-trihydroxy-5β-cholan-24-oylglycine
3Α,7α,12α-trihydroxy-5β-cholanic acid-24-glycine
3Α,7α,12α-trihydroxy-N-(carboxymethyl)-5β-cholan-24-amide
a,b-Hydroxypropionate
a,b-Hydroxypropionic acid
a-Aminoglutarate
a-Aminoglutaric acid
Acetylglucosamine
Acide glutamique
Acido glutamico
ácido glutámico
Acidum glutamicum
Aciglut
Aethanolamin
a-Glutamate
a-Glutamic acid
alpha,beta-Hydroxypropionate
alpha,beta-Hydroxypropionic acid
alpha-Aminoglutarate
alpha-Aminoglutaric acid
alpha-Glutamate
alpha-Glutamic acid
Aluminum L glutamate
Aluminum L-glutamate
Aminoethanol
Aminoglutarate
Aminoglutaric acid
b-Aminoethanol
b-Aminoethyl alcohol
beta-Aminoethanol
beta-Aminoethyl alcohol
beta-Ethanolamine
beta-Hydroxyethylamine
b-Ethanolamine
b-Hydroxyethylamine
Cholylglycine
Colamine
D Glutamate
D1,3,5(10)-Estratrien-3-ol-17-one
D-2,3-Dihydroxypropanoic acid
D-GlcNAc
D-Glutamate
|
D-Glycerate
D-Glyceric acid
D-GroA
E
E 620
E620
E-620
Envision conditioner PDD 9020
Estrone, (+-)-isomer
Estrone, (8 alpha)-isomer
Estrone, (9 beta)-isomer
Estrovarin
ETA
Ethylolamine
FEMA NO. 3285
Follicular hormone
Folliculin
Glt
Glu
Glusate
Glut
Glutacid
Glutamate
Glutamate, potassium
GLUTAMIC ACID
Glutamic acid, (D)-isomer
Glutamicol
Glutamidex
Glutaminate
Glutaminic acid
Glutaminol
Glutaton
Glycerate
Glycine cholate
Glycinol
Glycocholate
Glycocholate sodium
Glycocholic acid, sodium salt
Glycoreductodehydrocholic acid
Glycylcholate
Glycylcholic acid
Hauck brand OF estrone
Hea
H-Glycinol
Hyrex brand OF estrone
INS NO.620
INS-620
Kestrone
L Glutamate
L Glutamic acid
L-(+)-Glutamate
L-(+)-Glutamic acid
L-a-Aminoglutarate
L-a-Aminoglutaric acid
L-alpha-Aminoglutarate
L-alpha-Aminoglutaric acid
L-Glu
L-Glu|L-glutamate|poly-L-glutamate
L-GLUTAMATE
L-Glutamate, aluminum
L-GLUTAMIC ACID
L-Glutaminate
L-Glutaminic acid
L-Glutaminsaeure
MEA
Monoaethanolamin
MONOETHANOLAMINE
N Acetyl D glucosamine
N-(Carboxymethyl)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-amide
N-(Carboxymethyl)-3α,7α,12α-trihydroxy-5β-cholan-24-amide
N-[(3a,5b,7a,12a)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3alpha,5beta,7alpha,12alpha)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3Α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]glycine
N-Acetylchitosamine
N-Acetyl-D-glucosamine
N-Choloylglycine
N-Choloyl-glycine
NSC-143503
Oestrone
Olamine
Potassium glutamate
R-Glycerate
R-Glyceric acid
Unigen
Vortech brand OF estrone
Wehgen
Α,β-hydroxypropionate
Α,β-hydroxypropionic acid
Β-aminoethanol
Β-aminoethyl alcohol
Β-ethanolamine
Β-hydroxyethylamine
|
|
43 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
44 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
45 |
|
Veliparib |
Investigational |
Phase 1, Phase 2 |
|
912444-00-9 |
11960529 |
Synonyms:
(2R)-2-(7-CARBAMOYL-1H-BENZIMIDAZOL-2-YL)-2-METHYLPYRROLIDINIUM
2-((2R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE
2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
2-(2-Methylpyrrolidin-2-yl)-1H-1,3-benzodiazole-7-carboximidate
2-(2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimadazole-4-carboxamide
|
2-[(R)-2-METHYLPYRROLIDIN-2-YL]-1H-BENZIMIDAZOLE-4-CARBOXAMIDE
ABT 888
ABT-888
PARP-1 INHIBITOR ABT-888
VELIPARIB
|
|
46 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
47 |
|
Immune Checkpoint Inhibitors |
|
Phase 2 |
|
|
|
48 |
|
Adjuvants, Immunologic |
|
Phase 2 |
|
|
|
49 |
|
Keratolytic Agents |
|
Phase 2 |
|
|
|
50 |
|
Dermatologic Agents |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show all 37)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) |
Completed |
NCT01317615 |
Phase 4 |
RAD001;Paclitaxel;Carboplatin |
2 |
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer |
Completed |
NCT00020709 |
Phase 3 |
cisplatin;docetaxel;etoposide;gefitinib |
3 |
Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC |
Completed |
NCT00021060 |
Phase 2, Phase 3 |
paclitaxel;carboplatin |
4 |
Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer |
Completed |
NCT00005838 |
Phase 3 |
shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel |
5 |
A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG |
Completed |
NCT00002852 |
Phase 3 |
paclitaxel;carboplatin |
6 |
A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer |
Completed |
NCT00049543 |
Phase 3 |
gefitinib |
7 |
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
NCT00946712 |
Phase 3 |
Carboplatin;Paclitaxel |
8 |
Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC |
Completed |
NCT03044626 |
Phase 2 |
Radiotherapy;Nivolumab |
9 |
A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients With Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC) |
Completed |
NCT00950365 |
Phase 2 |
Erlotinib Hydrochloride;Pemetrexed Disodium |
10 |
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer |
Completed |
NCT01642251 |
Phase 1, Phase 2 |
Cisplatin;Etoposide;Veliparib;Placebo |
11 |
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy |
Completed |
NCT01294306 |
Phase 2 |
Akt Inhibitor MK2206;Erlotinib Hydrochloride |
12 |
Phase II Trial of OSI-774 (NSC-718781) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2 |
Completed |
NCT00087412 |
Phase 2 |
erlotinib hydrochloride |
13 |
A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
NCT00368992 |
Phase 2 |
paclitaxel |
14 |
ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study |
Completed |
NCT00040794 |
Phase 2 |
paclitaxel;carboplatin;gefitinib |
15 |
A Phase II Trial of Docetaxel Plus Cetuximab and Docetaxel Plus Bortezomib (NSC #681239, IND #58443) in Advanced Non-Small Cell Lung Cancer Patients With Performance Status (PS) 2 |
Completed |
NCT00118183 |
Phase 2 |
docetaxel;bortezomib |
16 |
Phase II Study of Sequential Dose-Dense Chemotherapy and Dose-Intense Erlotinib for the Initial Treatment of Advanced Non-Small Cell Lung Cancer |
Completed |
NCT01557959 |
Phase 2 |
cisplatin;erlotinib hydrochloride;docetaxel |
17 |
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer |
Recruiting |
NCT05198830 |
Phase 2 |
Cisplatin;Methoxyamine;Pemetrexed |
18 |
A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation |
Recruiting |
NCT02264210 |
Phase 2 |
Icotinib |
19 |
Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR |
Active, not recruiting |
NCT03110978 |
Phase 2 |
|
20 |
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer |
Active, not recruiting |
NCT00334815 |
Phase 2 |
Cisplatin;Docetaxel;Etoposide |
21 |
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811) |
Active, not recruiting |
NCT01386385 |
Phase 1, Phase 2 |
Carboplatin;Paclitaxel;Veliparib |
22 |
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) |
Active, not recruiting |
NCT03345810 |
Phase 2 |
Durvalumab;Vinorelbine;Gemcitabine;nab-Paclitaxel;Carboplatin |
23 |
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study) |
Active, not recruiting |
NCT03845296 |
Phase 2 |
Rucaparib |
24 |
Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC |
Active, not recruiting |
NCT02186847 |
Phase 2 |
Carboplatin;Metformin;Paclitaxel |
25 |
A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System |
Not yet recruiting |
NCT05566223 |
Phase 1, Phase 2 |
Fludarabine;Cyclophosphamide;Aldesleukin;Pembrolizumab |
26 |
A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab With or Without IMC-A12 in Patients With Advanced Non-squamous, Non-small Cell Lung Cancer |
Terminated |
NCT00955305 |
Phase 2 |
Carboplatin;Paclitaxel |
27 |
S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy |
Terminated |
NCT02134912 |
Phase 2 |
crizotinib;pemetrexed disodium |
28 |
A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer |
Completed |
NCT02535325 |
Phase 1 |
Cisplatin;Methoxyamine;Methoxyamine Hydrochloride;Pemetrexed;Pemetrexed Disodium |
29 |
Phase I Study of Thoracic Radiotherapy and Concurrent Chemotherapy With Soy Isoflavones in Stage III NSCLC (Non-Small Cell Lung Cancer) Patients |
Completed |
NCT01958372 |
Phase 1 |
cisplatin;etoposide;pemetrexed disodium |
30 |
A Phase I Study of Light Dose for Photodynamic Therapy(PDT) Using 2-[ 1-hexyloxyethel]-2-devinyl Pyropheophorbide-a (HPPH) for Treatment of Non-small Cell Carcinoma in Situ or Non-small Cell Microinvasive Carcinoma. A Dose Ranging Study |
Completed |
NCT01668823 |
Phase 1 |
HPPH;photodynamic therapy |
31 |
A Safety and Feasibility Study of Bevacizumab With Paclitaxel, Carboplatin and Chest Radiotherapy in Patients With Locally Advanced Non-Small Lung Cancer |
Terminated |
NCT00369551 |
Phase 1 |
paclitaxel;carboplatin |
32 |
A Phase I Study Of OSI-774 (NSC #718781)-Based Multimodality Therapy For Inoperable Stage III Non Small Cell Lung Cancer |
Terminated |
NCT00042835 |
Phase 1 |
cisplatin;etoposide;erlotinib hydrochloride;docetaxel;paclitaxel;carboplatin |
33 |
A Phase I Image-Guided Adaptive Radiotherapy Study Using Active Breathing Control (ABC) and Simultaneous Integrated Boost for Patients With Inoperable Non-Small Cell Lung Cancer |
Withdrawn |
NCT02059967 |
Phase 1 |
Paclitaxel;carboplatin |
34 |
Evaluation of PD-L1 Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC-GFPC 03-2017) |
Completed |
NCT03305133 |
|
|
35 |
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
Recruiting |
NCT02194738 |
|
Carboplatin;Cisplatin;Crizotinib;Erlotinib;Gemcitabine Hydrochloride;Paclitaxel;Pemetrexed;Pemetrexed Disodium |
36 |
Integrative Analysis of Large-cell Lung Carcinoma |
Recruiting |
NCT02917369 |
|
|
37 |
Image-Guided Hypofractionated Radiotherapy With Stereotactic Boost and Chemotherapy for Inoperable Stage II-III Non-Small Cell Lung Cancer |
Active, not recruiting |
NCT01345851 |
|
carboplatin;paclitaxel |
|